(Reuters) - Regado Biosciences Inc said it stopped enrollment in the late-stage trial for its lead drug after an independent committee recommended raised serious concerns of allergic reactions to the experimental blood thinner.
via Reuters: Health News Read More Here..
No comments:
Post a Comment